Control Bionics Reports Quarterly Activities for June 2026
Key points
- Completed Tranche 1 of A$9.8M capital raising
- Professor Nicholas Opie joins Board as strategic advisor
- US wholesale revenue momentum building
- NextLevel iOS device program on track for Q1FY27
- NeuroStrip commercial activity expanding
Full summary
Control Bionics Limited announced its Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026. Key highlights include the completion of Tranche 1 of its A$9.8 million capital raising, the addition of Professor Nicholas Opie to the Board, and increasing US wholesale revenue. The NextLevel iOS device program is on track for a Q1FY27 launch, and NeuroStrip commercial activity is expanding across sports performance, rehabilitation, and research settings. The company also entered into a $400,000 loan facility secured against its anticipated FY26 R&D tax incentive refund. Despite challenges such as NDIS approval delays in Australia and a slower-than-expected transition from retail to wholesale in North America, the company remains focused on disciplined execution and progressing towards key strategic milestones.
Guidance
Completion of Tranche 2 of capital raise expected in August 2026
Outlook
The company expects the NDIS environment to remain challenging in the near term and the North American transition to continue over coming quarters.
Summary generated by a large language model. Please interpret with care.